Abstract:Objective:To systematically evaluate the non-fatal heart failure risk occurring in type 2 diabetic patients receiving rosiglitazone therapy.Methods:Medline,ClinicalTrials.gov website and GlaxoSmithKline(GSK) website were searched using "rosiglitazone","randomized clinical trial" and "human'as the keywords from the inception to 31 August,2010.The randomized controlled trials(RCT) to compare non-fatal heart failure risk of rosiglitazone and other hypoglycemic drugs in patients with type 2 diabetes mellitus were collected and meta-analysis were conducted.According to the treatment course,diabetes duration,therapeutic model and type of control,all RCT were divided into different subgroups to undergo meta-analysis;and sensitivity analysis and cumulative meta-analysis were conducted further.Results:A total of 678 related articles were searched and 170 trials were obtained according to the inclusion and exclusion criteria.Of the 170 trials,99 were openly published on Medline or the website of ClinicalTrials.gov and 71 were published on the website of GSK.The results of meta-analysis showed that the odds ratio(OR) for nonfatal heart failure in the rosiglitazone group was 1.24(95%CI:0.99-1.55,P = 0.065),compared with the control group.The results of meta-analysis in subgroups showed that the OR for non-fatal heart failure in the rosiglitazone group were 1.42(95%CI: 1.06-1.90,P=0.019) and 1.01(95%CI:0.71-1.44,P = 0.958) in the 99 openly published studies and the 71 studies published on the website of GSK,respectively;the OR for non-fatal heart failure in the rosiglitazone group was 1.62(95%CI:1.17-2.23,P = 0.004) in the 30 studies with the treatment course of≥52 weeks.In the 21 openly published studies with the treatment course of≥52 weeks and the 33 studies with the duration of diabetes of≥5 and<10 years,the OR for non-fatal heart failure in the rosiglitazone groups were 1.79(95%CI:1.22-2.64,P = 0.003) and 1.55(95%CI:1.06-2.26,P= 0.025),respectively.The results of cumulative meta-analysis showed that the OR value was influenced by the results of the large scale RCT(RECORD) 2009,and there was a positive turning point in 2009.The results of a meta-analysis of the 43 trials with a JADA score of≥3 showed that the OR for non-fatal heart failure was 1.62(95%CI:1.17-2.23,P=0.004);of them,the OR values for the 16 trials with the treatment course of≥52 weeks,the 13 trials with the duration of diabetes of≥5 and<10 years,and the 19 trials with combined drug therapy were 1.79(95%CI:1.24-2.57,P=0.002),1.76(95%CI:1.15-2.71,P =0.010),and 1.68(95%CI:1.11-2.53,P = 0.014), respectively.Conclusion:Rosiglitazone may increase the non-fatal heart failure risk in the patients with type 2 diabetes mellitus, particularly in those with long duration of diabetes,receiving long-term medication use and combined drug therapy.

Toxicometabolomics-based cardiotoxicity evaluation of Thiazolidinedione exposure in human-derived cardiomyocytes

Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human‐derived cardiomyocytes

Metabonomic Profiling Revealed an Alteration in Purine Nucleotide Metabolism Associated with Cardiac Hypertrophy in Rats Treated with Thiazolidinediones

Recent Findings Concerning Thiazolidinediones in the Treatment of Diabetes

Reevaluation on the Adverse Effects of Thiazolidinediones

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells

The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus

Cardioprotective effects of acute rosiglitazone treatment

Efficacy and safety of rosiglitazone hydrochloride in the treatment of patients with type 2 diabetes mellitus

Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes

Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis

Non-fatal heart failure risk occurring in type 2 diabetic patients receiving rosiglitazone therapy:a meta-analysis

Pioglitazone is a forgotten hypoglycemic drug with proven cardioprotective and nephroprotective properties

4-Thiazolidinone-based derivatives do not affect differentiation of mouse embryo fibroblasts (3T3-L1 cell line) into adipocytes

Rosiglitazone-induced changes in the oxidative stress metabolism and fatty acid composition in relation with trace element status in the primary adipocytes

PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.

Identification of an allosteric hotspot for additive activation of PPARγ in antidiabetic effects

Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.

Assessment of anti-hyperglycemic and anti-hyperlipidemic effects of thiazolidine-2,4-dione derivatives in HFD-STZ diabetic animal model